System for identifying and controlling high death risk of hypertension crowd and storage medium

Abstract

The invention relates to the technical field of digital medical treatment, in particular to a system for identifying and controlling the high death risk of hypertension crowds and a storage medium, a computer readable storage medium stores a computer program, the computer program comprises a program instruction, and when the program instruction is executed by a processor, the processor executes the following steps: selecting a target measurement crowd, acquiring serum folic acid and vitamin B12 levels of the target measurement population; calculating a serum vitamin B12-folic acid ratio based on the serum folic acid and serum vitamin B12 levels; performing multi-level processing on the serum vitamin B12-folic acid ratio to obtain a multi-level analysis result, and evaluating the correlation between the serum vitamin B12-folic acid ratio and the total cause death risk based on the multi-level analysis result; according to the method, all-cause death risks of target measurement crowds are predicted in combination with correlation, high-risk death crowds are screened out based on risk prediction results, folic acid is supplemented to the high-risk death crowds to reduce the all-cause death risks, and important supplement of death risk prediction and control is achieved.

Description

Technical Field

[0001] The present invention relates to the field of digital medical technology, and in particular to a system and a storage medium for identifying and controlling high mortality risk in hypertensive population. Background Art

[0002] Mortality, as one of the core indicators for assessing population health, is crucial for identifying and implementing early preventive measures for groups at high risk of death. At present, there is a need to build a simple and objective assessment system that is independent of traditional risk factors such as age, gender, blood pressure, blood sugar, blood lipids, renal function, and changes in blood pressure during treatment, so as to accurately identify individuals with a higher risk of death among hypertensive patients and reduce the risk of death of the relevant individuals by implementing easy-to-operate intervention strategies.

[0003] Folic acid and vitamin B12 are water-soluble B vitamins that are essential for human carbon metabolism. They are vital to the human body. Previous studies have revealed that the deficiency of folic acid or vitamin B12 can increase the concentration of plasma homocysteine, thereby increasing the risk of cardiovascular and cerebrovascular diseases. In addition, folic acid supplementation has been proven to effectively reduce the risk of stroke, but the direct effect on the risk of death is not obvious. On the other hand, the relationship between vitamin B12 levels and the risk of death is inconsistent. Some studies have pointed out that the two are positively correlated, while other studies have not reached the same conclusion. It can be seen that the difference in conclusions lies in the fact that previous studies have not fully considered the potential synergistic effects between nutrients, so the impact relationship needs to be explored and analyzed in depth. Summary of the invention

[0004] In view of the deficiencies in the prior art, in the first aspect, the present invention provides a computer-readable storage medium, characterized in that the computer-readable storage medium stores a computer program, the computer program includes program instructions, and the program instructions, when executed by a processor, cause the processor to perform the following steps: select a target measurement population, obtain serum folate and vitamin B12 levels of the target measurement population; calculate the serum vitamin B12-folate ratio based on the serum folate and serum vitamin B12 levels; perform multi-level processing on the serum vitamin B12-folate ratio and obtain multi-level analysis results, and evaluate the correlation between the serum vitamin B12-folate ratio and the risk of all-cause death based on the multi-level analysis results; predict the risk of all-cause death of the target measurement population in combination with the correlation, and screen out a high-risk population for death based on the risk prediction results, and supplement folic acid to the high-risk population for death to reduce the risk of all-cause death. The present invention selects, analyzes data, predicts and identifies, and controls risks for the target measurement population, providing a more comprehensive and personalized risk identification and control solution for high-risk groups.

[0005] Optionally, selecting a target measurement population, and obtaining the serum folate and vitamin B12 levels of the target measurement population includes: selecting the target measurement population using a baseline survey method, wherein the target measurement population includes a hypertensive population with complete serum folate and vitamin B12 data. The present invention uses a baseline survey method to select a hypertensive population with complete folate and B12 data, which helps to ensure the scientificity and rigor of the research results and provides important guidance for the clinical management of hypertensive patients.

[0006] Optionally, selecting a target measurement population and obtaining the serum folate and vitamin B12 levels of the target measurement population includes: introducing a chemiluminescence immunoassay, and measuring the target measurement population using the chemiluminescence immunoassay to obtain the serum folate and vitamin B12 levels of the target measurement population. The present invention uses the chemiluminescence immunoassay to measure the target measurement population, further ensuring the accuracy and reliability of the test data.

[0007] Optionally, calculating the serum vitamin B12-folate ratio based on the serum folate and serum vitamin B12 levels includes: obtaining ratio analysis information of serum vitamin B12 and folate based on the serum vitamin B12-folate ratio. The ratio analysis information of the present invention is of great significance for the diagnosis and screening of diseases, the assessment of nutritional status, and the monitoring of treatment effects.

[0008] Optionally, the serum vitamin B12-folate ratio is subjected to multi-level processing and a multi-level analysis result is obtained, and the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality is evaluated based on the multi-level analysis result, including: setting a multi-level processing scheme, the multi-level processing scheme including a quartering process; the ratio analysis information is subjected to a quartering process and a multi-level analysis result is obtained, the result including the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality. The present invention performs multi-level processing on the treatment data and obtains a multi-level analysis result through a quartering process, which helps to improve the analysis accuracy, reveal potential trends, and promote scientific research progress.

[0009] Optionally, the serum vitamin B12-folate ratio is multi-level processed and a multi-level analysis result is obtained, and the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality is evaluated based on the multi-level analysis result, including: setting a ratio reference value according to the multi-level analysis result; and setting a serum vitamin B12-folate low ratio group and a serum vitamin B12-folate high ratio group based on the ratio reference value and the multi-level analysis result. The present invention sets a ratio reference value and grouping, which can clearly define the relationship between different B12-folate ratio intervals and the risk of all-cause mortality.

[0010] Optionally, the serum vitamin B12-folate ratio is multi-level processed and a multi-level analysis result is obtained, and the correlation between the serum vitamin B12-folate ratio and the risk of all-cause death is evaluated based on the multi-level analysis result, including: evaluating the correlation between the serum vitamin B12-folate ratio and the risk of all-cause death according to the serum vitamin B12-folate low ratio group and the serum vitamin B12-folate high ratio group, wherein the correlation includes that the serum vitamin B12-folate high ratio group presents a high risk of all-cause death. The present invention divides the ratio group into a low ratio group and a high ratio group, and can more finely analyze the impact of different ratio ranges on the risk of all-cause death, avoiding the evaluation bias caused by a single ratio level.

[0011] Optionally, the all-cause mortality risk of the target measurement population is predicted in combination with the correlation, and a high-risk population for death is screened out based on the risk prediction results, and folic acid is supplemented to the high-risk population for death to reduce the risk of all-cause mortality, including: identifying and predicting the all-cause mortality risk of the target measurement population in combination with the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality, and obtaining a risk prediction result, wherein the risk prediction result includes a high all-cause mortality risk in the serum vitamin B12-folate high ratio group; and formulating a folic acid supplementation plan for the high-risk population for death based on the risk prediction results. The present invention simultaneously considers the correlation and multi-level analysis results to analyze the relationship between folic acid and the serum vitamin B12-folate ratio on the risk of all-cause mortality, and derives a specific relationship of action, which helps to deepen the understanding and assessment of risk situations.

[0012] Optionally, the all-cause mortality risk of the target measurement population is predicted in combination with the correlation, and a high-risk population for death is screened out based on the risk prediction results, and folic acid is supplemented to the high-risk population for death to reduce the risk of all-cause mortality, including: setting a protective effect relationship in the folic acid supplementation regimen, the protective effect relationship including folic acid supplementation therapy and all-cause mortality risk in the serum vitamin B12-folate high ratio group; and controlling the all-cause mortality risk of the high-risk population for death based on the folic acid supplementation regimen. The present invention adjusts the treatment regimen based on the identification prediction results, which can ensure the effectiveness of the treatment regimen, and changes the treatment regimen for high-risk individuals to reduce the probability of all-cause mortality risk in the high-risk population for death.

[0013] On the other hand, the present invention also provides a system for identifying and controlling high mortality risk in hypertensive population, comprising an input device, a processor, an output device and a memory, wherein the input device, the processor, the output device and the memory are interconnected, the memory comprises a computer-readable storage medium as described in the first aspect of the present invention, the memory is used to store a computer program, the computer program comprises program instructions, and the processor is configured to call the program instructions. The system provided by the present invention has a compact structure, strong applicability, and greatly improves the operating efficiency. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 is a flow chart of program instructions in a computer-readable storage medium provided by the present invention; Figure 2 It is a schematic diagram of the relationship between the serum vitamin B12-folate ratio and the adjusted risk of death in the control group treated with enalapril alone in the present invention; Figure 3 It is a schematic diagram of the relationship between the folic acid supplementation treatment regimen and the risk of death in the high serum vitamin B12 to folic acid ratio group and the low serum vitamin B12 to folic acid ratio group of the present invention; Figure 4 It is a schematic diagram of the structure of the system for identifying and controlling high mortality risk of hypertensive people according to the present invention. DETAILED DESCRIPTION

[0015] The specific embodiments of the present invention will be described in detail below. It should be noted that the embodiments described herein are only for illustration and are not intended to limit the present invention. In the following description, a large number of specific details are set forth in order to provide a thorough understanding of the present invention. However, it is obvious to those of ordinary skill in the art that these specific details do not need to be adopted to implement the present invention. In other examples, in order to avoid confusing the present invention, known circuits, software or methods are not specifically described.

[0016] Throughout the specification, references to "one embodiment," "an embodiment," "an example," or "an example" mean that a particular feature, structure, or characteristic described in conjunction with the embodiment or example is included in at least one embodiment of the present invention. Therefore, the phrases "in one embodiment," "in an embodiment," "an example," or "an example" appearing in various places throughout the specification do not necessarily all refer to the same embodiment or example. In addition, particular features, structures, or characteristics may be combined in one or more embodiments or examples in any suitable combination and / or subcombination. In addition, it should be understood by those of ordinary skill in the art that the figures provided herein are for illustrative purposes and that the figures are not necessarily drawn to scale.

[0017] See also Figure 1 In one embodiment, the present invention provides a computer-readable storage medium, wherein the computer-readable storage medium stores a computer program, wherein the computer program includes program instructions, and when the program instructions are executed by a processor, the processor performs the following steps: S1. Select the target population for measurement and obtain the serum folate and vitamin B12 levels of the target population for measurement. The specific implementation steps and related contents are as follows: The target measurement population is selected using the baseline survey method. In the embodiment, the target measurement population mainly includes the hypertensive population with complete serum folate and vitamin B12 data. In this embodiment, in order to ensure the accuracy and reliability of the system identification results, the baseline survey method is used to select the target measurement population, that is, the hypertensive population with complete serum folate and vitamin B12 data is selected as the target measurement population. During the baseline survey, the relevant information of each participant was strictly reviewed to ensure the completeness and accuracy of the data. Finally, 20,499 hypertensive participants who met the relevant conditions were screened out for subsequent data measurement and identification analysis. The above target measurement population was used as an experimental research sample, which is helpful to further explore the potential relationship between serum folate and vitamin B12 and the risk of death in the hypertensive population, and lay a solid foundation for subsequent identification, analysis and research.

[0018] A treatment control group was set up based on the above target measurement population. In the embodiment, the treatment control group implemented a single enalapril antihypertensive treatment regimen; the above treatment control group implemented a single enalapril antihypertensive therapy, and the subjects in this group took 10 mg of enalapril tablets per day, one tablet per day. If blood pressure cannot be effectively controlled, the doctor may consider adding other antihypertensive drugs for auxiliary treatment.

[0019] At the same time, a treatment experimental group was set up according to the above-mentioned target measurement population. In the embodiment, the treatment experimental group implemented a combined treatment regimen of enalapril and folic acid. The subjects in this group took one enalapril folic acid tablet daily, which contained 10 mg of enalapril and 0.8 mg of folic acid. Similarly, if the blood pressure control effect is not ideal, other antihypertensive drugs can also be considered to enhance the treatment effect.

[0020] The setting method of the target measurement population and the treatment experimental group in this embodiment is only an optional condition of this embodiment. The setting method of the target population and the experimental group can be changed according to actual needs and experimental purposes. The present invention can select the target population and experimental group settings in a targeted manner, and can more effectively focus on key issues and reduce unnecessary interference factors, thereby accelerating the experimental process and improving the accuracy of the research results.

[0021] Furthermore, in this embodiment, a chemiluminescent immunoassay is introduced, and the target measurement population is measured using the chemiluminescent immunoassay to obtain the serum folate and vitamin B12 levels of the target measurement population.

[0022] In an optional embodiment, a chemiluminescent immunoassay is introduced to measure the target population to obtain the serum folate and vitamin B12 levels of the target population, and the specific contents are as follows: In the embodiment, chemiluminescence immunoassay is used as a measurement method for treatment data, which is conducive to the effective collection and accurate acquisition of relevant information of the target measurement population. That is, the concentration levels of serum folate and vitamin B12 of individuals in the target measurement population are determined by chemiluminescence immunoassay. Chemiluminescence immunoassay technology can quantitatively detect the serum folate content and vitamin B12 level of each participant in the target measurement population, thereby providing accurate and reliable biochemical indicator data for the follow-up, which is helpful to deeply understand the physiological response and efficacy of the target measurement population under a specific treatment plan.

[0023] Furthermore, the relevant technical means for measuring serum folate and vitamin B12 in this embodiment is only an optional condition of this embodiment. The data detection method of the target population can be changed according to actual needs and experimental purposes. The present invention can select the data detection method of the target population in a targeted manner, and can more effectively collect population data and key information, reduce unnecessary information interference factors, thereby accelerating the experimental process and improving the accuracy of the research results.

[0024] S2. Calculate the serum vitamin B12-folate ratio based on the above serum folate and serum vitamin B12 levels. The specific implementation steps and related contents are as follows: In the embodiment, the ratio analysis information of serum vitamin B12 and folic acid is obtained mainly based on the serum vitamin B12-folic acid ratio.

[0025] In order to deeply explore and analyze the correlation between the ratio of serum vitamin B12 to folate and the risk of all-cause mortality and its influencing mechanism, the serum vitamin B12-folate ratio was calculated based on the above-mentioned serum folate and serum vitamin B12 levels. In the process of calculating the serum vitamin B12-folate ratio, the specific values ​​of serum folate and serum vitamin B12 were first used to obtain the ratio result through relevant mathematical operations, which not only provided an intuitive reflection of the relative contents of vitamin B12 and folate in serum, but also was an important basis for subsequent in-depth analysis.

[0026] The calculated serum vitamin B12-folate ratio can further provide detailed analytical information on the ratio relationship between serum vitamin B12 and folic acid, which is crucial for understanding the interaction between the serum vitamin B12 and folate ratio and the risk of all-cause mortality and the human metabolic process.

[0027] The examples deeply explore and analyze the potential relationship between the ratio of serum vitamin B12 to folic acid and the risk of all-cause mortality, and reveal the impact of changes in the ratio on human health status and survival risk based on the serum vitamin B12-folic acid ratio. At the same time, it is helpful to further understand the physiological functions and metabolic pathways of vitamin B12 and folic acid in the human body, as well as their important roles in preventing diseases and maintaining health.

[0028] Furthermore, in the present embodiment, the analysis method for serum folate and the serum vitamin B12 levels is only an optional condition of the present embodiment. The relevant implementation steps and analysis methods can be optimized according to the requirements of the mortality risk analysis and the actual situation of the measured population. Different measured populations have different physiological characteristics, disease conditions or lifestyles. Therefore, adjusting the analysis steps and methods according to the actual situation can ensure that the research is closer to the target population and improve the applicability and practicality of the analysis method of the present invention.

[0029] S3. Perform multi-level processing on the serum vitamin B12-folate ratio and obtain multi-level analysis results. Based on the multi-level analysis results, evaluate the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality. The specific implementation steps and related contents are as follows: In this embodiment, a multi-level processing scheme is set up, and the above-mentioned multi-level processing scheme includes a four-equal division processing measure; the ratio analysis information is divided into four equal divisions and a multi-level analysis result is obtained. The multi-level analysis result in the embodiment mainly includes the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality.

[0030] The core of the multi-level processing strategy is to subdivide the target measurement population into four equal parts according to the ratio of vitamin B12 to folic acid at baseline, that is, the above-mentioned ratio analysis information, so as to describe the relevant characteristics of the target measurement populations with different baselines. In the embodiment, the four equal parts are defined as: the first quartile (<35 pg / ng), the second quartile (35-<50 pg / ng), the third quartile (50-<70 pg / ng), and the fourth quartile (≥70 pg / ng).

[0031] By dividing the above ratio analysis information into four equal parts, a clearer and more multi-level analysis result can be obtained. In this embodiment, the characteristic information obtained after the serum vitamin B12-folate ratio is divided into four equal parts is shown in Table 1.

[0032] Table 1 Information table of serum vitamin B12-folate ratio divided into four equal parts

[0033] The p-value in Table 1 is also called the probability value or significance level, which can be used to measure the probability that the data difference is caused by random errors, and helps to determine whether a certain experimental result is statistically significant. In the embodiment, if the p-value is less than the preset significance level, the experimental result is considered to be statistically significant.

[0034] Variables were expressed as mean ± SD or N (%); Based on the information in Table 1, the multi-level analysis results of the embodiment can be quickly obtained, and the data distribution of the 20,499 target measurement populations can be further understood, among which the median serum vitamin B12 level reached 380 pg / mL, and the median vitamin B12 to folic acid ratio was 50 pg / ng. Among them, among the participants with a higher vitamin B12 to folic acid ratio, the proportion of males and current smokers was relatively high. In addition, the above groups also showed the following characteristics: high body mass index (BMI), total cholesterol, triglycerides, fasting blood sugar, total homocysteine, creatinine and vitamin B12 levels; baseline blood pressure levels and average blood pressure levels during treatment were also high; however, high-density lipoprotein cholesterol (HDL-C) and serum folate levels were relatively low.

[0035] The ratio reference value is set according to the above multi-level analysis results; and based on the ratio reference value and the multi-level analysis results, a serum vitamin B12-folate low ratio group and a serum vitamin B12-folate high ratio group are set.

[0036] The ratio reference value is set according to the above multi-level analysis results.

[0037] In this embodiment, a vitamin B12 to folic acid ratio is determined as a reference benchmark according to the multi-level analysis results in Table 1, and two groups are divided based on the reference benchmark and the multi-level analysis results: a serum vitamin B12-folic acid low ratio group and a serum vitamin B12-folic acid high ratio group. Then, a comparative analysis of the data of the two groups is performed to help accurately assess the correlation between the vitamin B12 to folic acid ratio and the risk of all-cause mortality.

[0038] The above serum vitamin B12-folate low ratio group: ratio <70 pg / ng; serum vitamin B12-folate high ratio group: ratio ≥70 pg / ng; In the example, the correlation between the serum vitamin B12 to folate ratio and the risk of all-cause mortality was evaluated and compared by combining the serum vitamin B12 to folate ratio reference value (ratio is 70 pg / ng) and the multi-level analysis results. For relevant information, please see Table 2.

[0039] Table 2 Correlation analysis of serum vitamin B12-folate ratio and all-cause mortality risk in the enalapril monotherapy control group

[0040] In the analysis of Table 2, this embodiment comprehensively considered a variety of potential influencing factors, including but not limited to age, gender, polymorphism of the C677T site of the MTHFR gene, body mass index (BMI), systolic blood pressure and diastolic blood pressure, differences in research centers, total homocysteine ​​level, creatinine content, total cholesterol level, triglyceride level, high-density lipoprotein cholesterol (HDL-C) level, fasting blood glucose value, smoking habits, and average systolic blood pressure and diastolic blood pressure during treatment, and made necessary adjustments to the above-mentioned influencing factors to ensure the accuracy and reliability of subsequent analysis results.

[0041] The correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality was further evaluated based on the serum vitamin B12-folate low ratio group and the serum vitamin B12-folate high ratio group. The correlation in the embodiment includes that the serum vitamin B12-folate high ratio group presents a high risk of all-cause mortality.

[0042] In this example, the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality was evaluated mainly based on the information in Table 2.

[0043] After excluding a variety of traditional risk factors including age, gender, MTHFR gene C677T polymorphism, body mass index, blood pressure (systolic and diastolic), study center differences, total homocysteine, creatinine, total cholesterol, triglycerides, high-density lipoprotein cholesterol, fasting blood glucose, smoking habits, and average blood pressure during treatment, it was found that compared with the serum vitamin B12-folate low ratio group (ratio <70 pg / ng), the serum vitamin B12 to folate ratio was lower; the serum vitamin B12 to folate ratio was higher in the serum vitamin B12-folate high ratio group (ratio ≥70 pg / ng), and the risk of all-cause mortality faced by participants in the serum vitamin B12-folate high ratio group (ratio ≥70 pg / ng) was significantly increased. That is, based on relevant information analysis, the risk of all-cause mortality in the serum vitamin B12-folate high ratio group (ratio ≥70 pg / ng) was higher than that in the serum vitamin B12-folate low ratio group (ratio <70 pg / ng) (hazard ratio, 1.30), and the above association was statistically significant with a 95% confidence interval of 1.01 to 1.67.

[0044] Based on the above analysis information, it can be seen that the high serum vitamin B12-folate ratio group (ratio ≥ 70 pg / ng) is positively correlated with the risk of all-cause mortality. In this example, a schematic diagram of the relationship between the ratio of serum vitamin B12 and folic acid and the adjusted risk of mortality is further drawn. For details, please refer to Figure 2, where the solid line represents the point estimate of the relative risk ratio of all-cause mortality corresponding to different serum vitamin B12:folate ratios, and the two dotted lines represent the 95% confidence intervals of the corresponding relative risk ratios.

[0045] Figure 2 The association between serum vitamin B12:folate ratio and adjusted mortality risk in the enalapril monotherapy control group is visually demonstrated. Figure 2 It can be seen that there is a linear positive correlation between the serum vitamin B12-folate ratio and the adjusted risk of death, and this correlation is not interfered or affected by a variety of traditional risk factors, such as age, gender, polymorphism of the MTHFR gene C677T site, body mass index, blood pressure level (including systolic and diastolic blood pressure), different research centers, total homocysteine ​​concentration, creatinine content, blood lipid levels (total cholesterol, triglycerides, high-density lipoprotein cholesterol), fasting blood sugar value, smoking habits, and the average level of blood pressure during treatment. That is, as the ratio of vitamin B12 to folic acid in serum continues to increase, the risk of death faced by individuals also shows a gradually increasing trend, and the risk of death also gradually increases.

[0046] Based on the above analysis data and results, it can be seen that: under the condition of controlling a series of traditional risk factors and serum vitamin B12 and folic acid levels, the treatment control group using a single enalapril antihypertensive treatment regimen was compared with the treatment experimental group using a combined treatment regimen of enalapril and folic acid. The treatment experimental group (10 mg / day of enalapril and 0.8 mg / day of folic acid) can significantly reduce the risk of all-cause mortality in the group with a higher ratio of vitamin B12 to folic acid, that is, the high serum vitamin B12-folate ratio group (ratio ≥70 pg / ng), specifically, the hazard ratio was reduced to 0.74, and its 95% confidence interval was 0.54 to 1.00.

[0047] On the other hand, in people with a low vitamin B12 to folate ratio, that is, the low serum vitamin B12-folate ratio group (ratio <70 pg / ng), folic acid treatment did not show a significant effect on the risk of all-cause mortality, and its hazard ratio remained at 1.09, corresponding to a 95% confidence interval of 0.90 to 1.32. Further analysis showed that the interaction between the high and low vitamin B12 to folate ratio and folic acid treatment had a significant effect on the risk of all-cause mortality.

[0048] Based on the correlation analysis results of the high serum vitamin B12-folate ratio group and the low serum vitamin B12-folate ratio group, we drew a schematic diagram of the relationship between folic acid supplementation treatment and mortality risk in different ratio groups. For details, please see Figure 3, where HR, CI and p represent hazard ratio, confidence interval and p-value respectively, which are used together to evaluate the statistical significance of risk differences between different treatment groups. Furthermore, HR represents the ratio of two hazard rates, which is used to compare the probability of risk occurrence between the two groups; CI represents the probability interval, which is used to represent the uncertainty of the estimated value of a statistical parameter (such as HR), which gives the interval range that the true value of the parameter may fall into; P represents the probability of the observed data or more extreme data occurring, and is an indicator used to evaluate the results of statistical hypothesis testing.

[0049] In the embodiment Figure 3 The cumulative incidence of death between two groups of people with different serum vitamin B12-folate ratio levels after receiving different treatment regimens (with or without folic acid supplementation) was compared.

[0050] For people with higher levels of vitamin B12 and folic acid, that is, the high serum vitamin B12-folate ratio group (ratio ≥ 70 pg / ng), when this high-risk group only used enalapril for antihypertensive treatment, their cumulative mortality rate showed a baseline level; when they were treated with a combination drug containing 10 mg / day of enalapril and 0.8 mg of folic acid / day (enalapril folic acid tablets), their cumulative mortality rate showed a significant decrease compared with the enalapril treatment group alone, and the above decrease reached 28%, and this difference was statistically significant (P=0.034<0.05).

[0051] For people with low levels of vitamin B12 and folate, that is, the low serum vitamin B12-folate ratio group (ratio <70 pg / ng), in this low-risk population, no significant difference in the cumulative mortality rate was observed between the two groups, whether enalapril was used alone for antihypertensive treatment or a combination drug containing enalapril and folic acid was used. The above conclusion was statistically supported (P=0.516≥0.05).

[0052] In summary, based on Figure 3 The data showed that in people with a high serum vitamin B12-folate ratio, i.e., the high serum vitamin B12-folate ratio group (ratio ≥ 70 pg / ng), the use of enalapril folic acid tablets can significantly reduce the cumulative mortality rate compared with enalapril alone. However, in people with low vitamin B12 and folate levels, i.e., the low serum vitamin B12-folate ratio group (ratio < 70 pg / ng), the above two treatment regimens did not show a significant difference in reducing the risk of death.

[0053] Furthermore, in order to further analyze and evaluate the effect of folic acid supplementation therapy on the risk of all-cause mortality in the low serum vitamin B12-folate ratio group and the high serum vitamin B12-folate ratio group in the examples, the information on the effect of folic acid therapy on the risk of all-cause mortality in the high serum vitamin B12 and folate ratio group and the low serum vitamin B12 and folate ratio group in the examples was sorted out. Please refer to Table 3 for details.

[0054] Table 3 Analysis of the effect of folic acid treatment on the risk of all-cause mortality in the high and low ratio groups of serum vitamin B12 to folate

[0055] The data in Table 3 have been corrected and adjusted according to a variety of factors, including but not limited to age, gender, polymorphism of the C677T site of the MTHFR gene, body mass index (BMI), systolic and diastolic blood pressure levels, differences in research centers, folic acid concentrations, vitamin B12 levels, total homocysteine ​​content, creatinine values, blood lipid indexes (total cholesterol, triglycerides, high-density lipoprotein cholesterol), fasting blood sugar values, smoking habits, and average blood pressure levels during treatment (especially average systolic and diastolic blood pressure). The adjustment method of the embodiment is conducive to ensuring the accuracy and reliability of the analysis results, so as to more deeply understand the role and influence relationship between different related variables.

[0056] based on Figure 3 The information in Table 3 can accurately analyze and compare the cumulative incidence of death using a single enalapril antihypertensive treatment regimen and a combination drug (enalapril folic acid tablets) using enalapril 10 mg / day and 0.8 mg folic acid / day in people with different serum vitamin B12 and folate ratios, i.e., the low serum vitamin B12-folate ratio group and the high serum vitamin B12-folate ratio group.

[0057] In this example, serum vitamin B12 and folic acid levels were further adjusted, revealing the importance of the ratio of vitamin B12 to folic acid as an independent factor in predicting the risk of death and the benefit of folic acid treatment. Based on the above relevant information, it can be seen that even if the target individual has sufficient folic acid, when the vitamin B12 level is abnormally elevated, the serum vitamin B12-folic acid ratio is increased, that is, the serum vitamin B12-folic acid high ratio group (ratio ≥ 70 pg / ng) is reached, and the risk of death in this population will still increase. In response to this situation, increasing folic acid supplementation is an effective strategy to reduce the risk of death. The above findings not only deepen the understanding of the relationship between vitamin B12 and folic acid, but also provide solid scientific support for designing more precise intervention plans for people with specific ratio characteristics.

[0058] In this embodiment, the method of analyzing the effect of the B12-folate ratio on the risk of all-cause mortality in combination with experimental data is only an optional condition of this embodiment. The specific analysis method of the effect of different influencing factors on the risk of mortality can be adjusted according to the actual situation of the target population and the risk analysis objectives, which can more accurately capture and quantify the correlation between the B12-folate ratio and the risk of all-cause mortality, thereby providing more reliable analysis results.

[0059] S4. Combine the correlation to predict the all-cause mortality risk of the target population, and screen out the high-risk population based on the risk prediction results. Supplement folic acid to the high-risk population to reduce the risk of all-cause mortality. The specific implementation steps and related contents are as follows: Combined with the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality, the all-cause mortality risk of the target measurement population was identified and predicted, and the risk prediction results were obtained. The above risk prediction results included that the high serum vitamin B12-folate ratio group showed a high all-cause mortality risk; and a folic acid supplementation plan for the high-risk population for death was formulated based on the risk prediction results.

[0060] A protective effect relationship is set in the folic acid supplementation program, and the above protective effect relationship includes but is not limited to folic acid supplementation treatment and all-cause mortality risk in the group with high serum vitamin B12-folate ratio; and based on this folic acid supplementation program, the risk of all-cause mortality in the high-risk population can be controlled.

[0061] In an optional embodiment, the following strategy is used for the target measurement population to predict the risk of all-cause mortality and screen high-risk populations for folic acid supplementation intervention. The specific process and content are summarized as follows: First, the ratio of serum vitamin B12 to folate was used as a key indicator for identification, and the correlation between the ratio and the all-cause mortality risk of the target measurement population was analyzed, and then the all-cause mortality risk of the target measurement population was accurately predicted. The prediction results clearly pointed out that the group with a high serum vitamin B12-folate ratio faced a higher risk of all-cause mortality.

[0062] Subsequently, a folic acid supplementation program for people at high risk of death was designed based on the above risk prediction results. The above program aims to reduce the risk of all-cause mortality in high-risk groups through scientific and reasonable folic acid supplementation. A protective effect relationship was specially set in the folic acid supplementation program. This relationship mainly covers the reduction in the risk of all-cause mortality in the high serum vitamin B12-folate ratio group after receiving folic acid supplementation treatment. It not only reflects the targeted nature of folic acid supplementation, but also ensures the effectiveness and scientific nature of the intervention measures.

[0063] Ultimately, precise intervention will be implemented on the screened high-risk population for death based on the folic acid supplementation program, in order to effectively control and reduce the risk of all-cause mortality.

[0064] In this embodiment, the all-cause mortality risk of the target population is identified and predicted in combination with the correlation and interaction relationship, and the treatment plan for the high-risk population is adjusted according to the identification and prediction results to achieve control of the all-cause mortality risk of the high-risk population.

[0065] In this embodiment, the correlation and interaction relationships are comprehensively used to identify and predict the all-cause mortality risk of the target population. In addition, the treatment plan of the target population is adjusted in a targeted manner based on the results of the above identification and prediction, which helps to achieve effective control of its all-cause mortality risk.

[0066] Based on the relevant information and the effects, it can be seen that the high serum vitamin B12-folate ratio group is a key factor in increasing the risk of all-cause mortality. At the same time, folic acid treatment has shown significant results in reducing the risk of all-cause mortality associated with this high-risk ratio. The above findings highlight the important role of the vitamin B12 to folic acid ratio in assessing and controlling the risk of all-cause mortality, and further provide a simple and objective evaluation indicator.

[0067] Furthermore, the serum vitamin B12 and folic acid levels were corrected, further confirming that it is the ratio of vitamin B12 to folic acid itself, rather than the single folic acid or B12 level, that plays a decisive role in the risk of death or the benefit of folic acid intervention. In an optional embodiment, even if the individual's folic acid level is already very high, if the vitamin B12 level is abnormally elevated, resulting in an excessively high ratio in the serum vitamin B12-folic acid high ratio group, the risk of death will still increase. At this time, additional folic acid supplementation can effectively reduce the risk of death.

[0068] Different from existing studies, this invention is the first to evaluate the impact of the ratio of vitamin B12 to folic acid on the risk of all-cause mortality, and clarifies the important role of folic acid therapy in reducing the risk of all-cause mortality associated with a high-risk ratio. The method proposed in this invention not only has important clinical application value, but also provides a new perspective and strategy for the field of public health.

[0069] Furthermore, in the present embodiment, the identification and prediction method of the target population's all-cause mortality risk is merely an optional condition of the present embodiment. The identification and prediction method in the embodiment can be optimized according to actual analysis needs and the actual situation of the all-cause mortality risk, and can more accurately capture and analyze the target population's risk of death, thereby improving the accuracy and reliability of the analysis results, and at the same time making the present invention more in line with the actual situation of the target population, thereby enhancing the applicability and practicality of the method of the present invention.

[0070] For further information, see Figure 4In an optional embodiment, a system for identifying and controlling high mortality risk in people with hypertension also includes an input device, an output device and a processor, wherein the input device, the processor, the memory and the output device are interconnected to achieve information exchange and data processing.

[0071] In this embodiment, the input device is used to provide input related data or instructions to the system. In the system for identifying and controlling high mortality risk of people with hypertension, the input device may include common human-computer interaction interface devices such as keyboard, mouse, touch screen, etc. Through the input device, doctors or researchers can input key parameters of the target population.

[0072] The processor is the core component of the system, responsible for executing computer program instructions, processing and analyzing data. In the system for identifying and controlling high mortality risk in people with hypertension, the processor analyzes and interprets the input data by running pre-programmed algorithms and models. The processor can be a central processing unit, a graphics processing unit or other dedicated processing unit.

[0073] The memory is used to store computer programs, data and parameters required by the system. It may include random access memory for temporary data storage and processing, and persistent memory (such as a hard disk or solid state drive) for long-term storage and preservation of data. In a system for identifying and controlling high mortality risk in hypertensive people, the memory can store treatment data, experimental data, and action relationship analysis information, etc.

[0074] The output device is used to present the results of system processing and analysis to the user or external device. In the system for identifying and controlling the high risk of death in people with hypertension, the output device can be a display, a printer, a chart drawing device, etc. Through the output device, the system can display the prediction analysis results of the risk of death, which can be used as a reference for doctors, researchers or patients to assist in decision-making and communication.

[0075] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

Claims

1. A computer-readable storage medium, characterized in that: The computer readable storage medium stores a computer program, wherein the computer program includes program instructions, and when the program instructions are executed by a processor, the processor performs the following steps: Select the target measurement population and obtain the serum folate and vitamin B12 levels of the target measurement population; calculating a serum vitamin B12-folate ratio based on the serum folate and the serum vitamin B12 levels; Performing multi-level processing on the serum vitamin B12-folate ratio and obtaining a multi-level analysis result, and evaluating the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality based on the multi-level analysis result; The all-cause mortality risk of the target measurement population is predicted based on the correlation, and the high-risk population for death is screened out based on the risk prediction results. Folic acid is supplemented to the high-risk population to reduce the all-cause mortality risk.

2. The computer-readable storage medium according to claim 1, wherein: The step of selecting a target population for measurement and obtaining serum folate and vitamin B12 levels of the target population for measurement includes: The target measurement population was selected using a baseline survey method, and the target measurement population included hypertensive people with complete serum folate and vitamin B12 data.

3. The computer-readable storage medium according to claim 2, wherein: The step of selecting a target population for measurement and obtaining serum folate and vitamin B12 levels of the target population for measurement includes: A chemiluminescent immunoassay is introduced, and the target measurement population is measured using the chemiluminescent immunoassay to obtain the serum folate and vitamin B12 levels of the target measurement population.

4. The computer-readable storage medium according to claim 3, wherein: Calculating the serum vitamin B12-folate ratio based on the serum folate and serum vitamin B12 levels comprises: The ratio analysis information of serum vitamin B12 and folic acid is obtained based on the serum vitamin B12-folic acid ratio.

5. The computer-readable storage medium according to claim 4, wherein: The multi-level processing of the serum vitamin B12-folate ratio and obtaining a multi-level analysis result, and evaluating the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality based on the multi-level analysis result include: Setting a multi-level processing scheme, wherein the multi-level processing scheme includes a quartering process; The ratio analysis information was divided into four equal parts and a multi-level analysis result was obtained, which included the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality.

6. The computer-readable storage medium according to claim 5, wherein: The multi-level processing of the serum vitamin B12-folate ratio and obtaining a multi-level analysis result, and evaluating the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality based on the multi-level analysis result include: Setting a ratio reference value according to the multi-level analysis results; A serum vitamin B12-folate low ratio group and a serum vitamin B12-folate high ratio group are set based on the ratio reference value and the multi-level analysis results.

7. The computer-readable storage medium according to claim 6, wherein: The multi-level processing of the serum vitamin B12-folate ratio and obtaining a multi-level analysis result, and evaluating the correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality based on the multi-level analysis result include: The correlation between the serum vitamin B12-folate ratio and the risk of all-cause mortality was evaluated based on the low serum vitamin B12-folate ratio group and the high serum vitamin B12-folate ratio group, and the correlation included that the high serum vitamin B12-folate ratio group presented a high risk of all-cause mortality.

8. The computer-readable storage medium according to claim 7, wherein: The method of predicting the all-cause mortality risk of the target measurement population in combination with the correlation, screening out a high-risk population for mortality based on the risk prediction result, and supplementing the high-risk population with folic acid to reduce the all-cause mortality risk includes: The all-cause mortality risk of the target population is identified and predicted by combining the correlation between the serum vitamin B12-folate ratio and the all-cause mortality risk, and a risk prediction result is obtained, wherein the high serum vitamin B12-folate ratio group presents a high all-cause mortality risk; A folic acid supplementation program for people at high risk of death is formulated based on the risk prediction results.

9. The computer-readable storage medium according to claim 8, wherein: The method of predicting the all-cause mortality risk of the target measurement population in combination with the correlation, screening out a high-risk population for mortality based on the risk prediction result, and supplementing the high-risk population with folic acid to reduce the all-cause mortality risk includes: A protective effect relationship is set in the folic acid supplementation regimen, wherein the protective effect relationship includes folic acid supplementation treatment and the risk of all-cause mortality in the high serum vitamin B12-folate ratio group; Based on the folic acid supplementation program, the risk of all-cause mortality in high-risk populations can be controlled.

10. A system for identifying and controlling high mortality risk in hypertensive population, characterized in that: The invention comprises an input device, a processor, an output device and a memory, wherein the input device, the processor, the output device and the memory are interconnected, the memory comprises a computer-readable storage medium as claimed in any one of claims 1 to 9, the memory is used to store a computer program, the computer program comprises program instructions, and the processor is configured to call the program instructions.

Images